All Monoclonal Antibodies articles – Page 2
-
ArticleCD24 emerges as the next macrophage checkpoint
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
-
NewsHIV antibody 04_A06 almost neutralises all strains
A newly discovered antibody, 04_A06, has shown unprecedented effectiveness against HIV, neutralising 98.5 percent of tested strains and permanently suppressing the virus in humanised mice.
-
NewsNew UCLA drug could restore heart and organ function
UCLA researchers have developed a monoclonal antibody, AD-NP1, that blocks ENPP1 to enhance heart repair and reduce scar tissue.
-
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
-
NewsBlocking SLAMF6 enables T cells to kill leukaemia cells
Researchers have discovered a surface protein that helps acute myeloid leukaemia cells evade the immune system, offering potential insights to aid the development of new treatments.
-
ArticleMass spectrometry workflows powering the future of biologics
Analysing complex biologics is one of drug discovery’s biggest challenges. At Genentech, Rachel Shi is developing MS workflows that deliver clearer answers, faster.
-
NewsNovltex: new antibiotic targets antimicrobial resistance
Scientists at the University of Liverpool have discovered Novltex, a new class of antibiotics that shows potent activity against deadly multidrug-resistant bacteria such as MRSA.
-
ArticlePDX models are back – and they’re exposing what cell lines missed
As cancer drugs continue to fail in translation, researchers are turning back to patient-derived xenograft (PDX) models – this time with better science. Could they be the missing link between the lab and the clinic?
-
NewsAnti-linker antibodies: a universal key for CAR-T detection
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
-
ArticleLab of the future: four technologies to watch
From precision proteomics to AI-powered immune profiling, next-generation laboratory technologies are changing how new therapies are discovered and developed. Here are four innovations set to shape the lab of the future - and the future of drug discovery.
-
NewsThree powerful antibodies discovered with potential to treat mpox
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
-
NewsChikungunya’s 2025 surge sparks urgent research response
The 2025 chikungunya outbreak has surged from the Indian Ocean to Europe, prompting an urgent global research response. With no antivirals and limited vaccine access, laboratories and biotech firms are under pressure to deliver solutions fast.
-
ArticleHow to select the optimal bispecific antibody format for therapeutic success
Choosing the right bispecific antibody format can make or break your therapy’s success. This article explores how format impacts function, manufacturability and development strategy - helping you make the best choice from the start.
-
NewsHow to select the optimal bispecific antibody format for therapeutic success
Discover the key scientific, strategic and manufacturing factors that could decide whether your bsAb succeeds in the clinic or stalls in development.
-
ArticleChallenges in developing robust potency assays for ADCs
Developing robust potency assays for Antibody-Drug Conjugates (ADCs) is crucial for ensuring their clinical success, but designing assays that meet both technical and regulatory standards is challenging. Here, Abzena’s CSO Campbell Bunce explores the complexities of assay development and the importance of ensuring accuracy, consistency and regulatory alignment for ADCs ...
-
ArticleLupus reimagined: targeting the cause, not just the symptoms
Engineered cell therapies are offering a potential new way to treat lupus – not by suppressing symptoms, but by reprogramming the immune system itself. For the first time, lasting remission looks like a real possibility.
-
ArticleWhy most T-cell engagers fail - and how to fix it
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.
-
ArticleAntibodies come full circle: biopharma back at the bench
Recombinant antibody technology is redefining research standards - bringing biopharma-grade precision, consistency, and customisation to the lab. Discover how advances like Fc engineering and chimerisation are accelerating progress from basic discovery to clinical insight.
-
ArticleFrom lab to clinic: the rise of Radio-DARPins in oncology
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
-
WebinarInnovating Obesity Drug Discovery: Trends, Challenges, and Translational Strategies
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk.